



CLAIM AMENDMENTS

1. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula PQ:



or a pharmaceutically acceptable salt thereof.

2. (currently amended) A pharmaceutical composition compound according to claim 1, of formula P or Q:



or a pharmaceutically acceptable salt thereof.

3. (currently amended) A pharmaceutical composition according to claim 1 comprising a pharmaceutically acceptable carrier and (1S,4R)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine according to claim 1 or a pharmaceutically acceptable salt thereof.


4. (currently amended) A pharmaceutical composition according to claim 1 comprising a pharmaceutically acceptable carrier and (1R,4S)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine according to claim 1 or a pharmaceutically acceptable salt thereof.

5. (cancelled)

6. (currently amended) A tablet or capsule according to ~~claim 5~~ any of claims 1-4.


7. (original) A method for treating CNS disorders in a human, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of:

(a) *(1R,4S)-trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



P ;

(b) *(1S,4R)-trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



Q ;

(c) a mixture of P and Q; or

(d) a pharmaceutically acceptable salt thereof.

8. (original) The method according to claim 7, wherein the CNS disorder is a mood disorder.

9. (original) The method according to claim 8, wherein the mood disorder is depression.

10. (previously presented) The method according to claim 7, wherein the CNS disorder is anxiety-related disorder.

11. (original) The method according to claim 10, wherein the anxiety-related disorder is obsessive compulsive disorder.

12. (original) The method according to claim 7, wherein the CNS disorder is a disruptive behavior disorder.

13. (original) The method according to claim 12, wherein the disruptive behavior disorder is one of attention deficit disorder (ADD) or attention deficit / hyperactivity disorder (ADHD).

14. (original) The method according to claim 7, wherein the CNS disorder is a sexual dysfunction.


15. (original) The method according to claim 7, wherein the CNS disorder is a substance abuse disorder.

16. (original) The method according to claim 7, wherein the CNS disorder is an eating disorder.


17. (original) A method according to claim 7, wherein the CNS disorder is premenstrual syndrome disorder.

18. (original) A method for the prophylaxis of migraine in a human, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of a compound chosen from:

(a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




(b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of P and Q; and
- (d) a pharmaceutically acceptable salt thereof.

19. (original) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of P and Q ; or
- (d) a pharmaceutically acceptable salt thereof, together with
- (e) a therapeutically effective amount of a D₂ antagonist, or a pharmaceutically acceptable salt thereof.

20. (original) The method according to claim 19, wherein the D₂ antagonist is olanzapine.

21. (cancelled)


22. (previously presented) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

(a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



P ;

(b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



Q ;

(c) a mixture of P and Q ; or

(d) a pharmaceutically acceptable salt thereof, together with

(e) a therapeutically effective amount of an antipsychotic agent, or a pharmaceutically acceptable salt thereof.


23. (previously presented) A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, the process comprising:

(a) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone with an excess of formic acid and formamide to provide *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide; and


(b) hydrolyzing the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide with aqueous acid,

yielding 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine.


24. (previously presented) A compound of formula:




25. (previously presented) A compound according to claim 24, of formula E:



26. (previously presented) A compound according to claim 24, of formula F:



27. (previously presented) A compound according to claim 24, of formula A, B, C, or D:



28. (previously presented) (1S,4R)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

29. (previously presented) (1R,4S)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

30. (previously presented) (1S,4S)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.

31. (previously presented) (1R,4R)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide according to claim 24.


32. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 24 to 31.

33. (previously presented) A tablet or capsule according to claim 32.


34. (previously presented) A method for treating CNS disorders in a human, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

35. (previously presented) A method according to claim 34, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of:


(a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




(b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



(c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



(d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



- (e) a mixture of **A** and **B**;
- (f) a mixture of **C** and **D**; or
- (g) a pharmaceutically acceptable salt thereof.

36. (previously presented) The method according to claim 34, wherein the CNS disorder is a mood disorder.

37. (previously presented) The method according to claim 36, wherein the mood disorder is depression.

38. (previously presented) The method according to claim 34, wherein the CNS disorder is anxiety-related disorder.

39. (previously presented) The method according to claim 38, wherein the anxiety-related disorder is obsessive compulsive disorder.

40. (previously presented) The method according to claim 34, wherein the CNS disorder is a disruptive behavior disorder.

41. (previously presented) The method according to claim 40, wherein the disruptive behavior disorder is one of attention deficit disorder (ADD) or attention deficit / hyperactivity disorder (ADHD).

42. (previously presented) The method according to claim 34, wherein the CNS disorder is a sexual dysfunction.

43. (previously presented) The method according to claim 34, wherein the CNS disorder is a substance abuse disorder.


44. (previously presented) The method according to claim 34, wherein the CNS disorder is an eating disorder.

45. (previously presented) A method according to claim 34, wherein the CNS disorder is premenstrual syndrome disorder.


46. (previously presented) A method for the prophylaxis of migraine in a human, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

47. (previously presented) A method according to claim 46, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of a compound chosen from:


(a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




(b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**B ;**

(c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide

**C ;**

(d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide


**D ;**

(e) a mixture of **A** and **B**;
 (f) a mixture of **C** and **D**; or
 (g) a pharmaceutically acceptable salt thereof.

48. (previously presented) A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.


49. (previously presented) A method according to claim 48, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

(a) (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




A ;

(b) (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




B ;

(c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



C ;

(d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide




- (e) a mixture of A and B;
- (f) a mixture of C and D; or
- (g) a pharmaceutically acceptable salt thereof, together with
- (h) a therapeutically effective amount of a D₂ antagonist, or a pharmaceutically acceptable salt thereof.

50. (currently amended) The method according to claim 48-49, wherein the D₂ antagonist is olanzapine.


51-53. (cancelled)

54. (previously presented) A method according to claim 48, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:


- (a) (1*S*,4*R*)-*N*-(4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)formamide




- (b) (1*R*,4*S*)-*N*-(4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)formamide



(c) (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



(d) (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide



(e) a mixture of **A** and **B**;
(f) a mixture of **C** and **D**; or
(g) a pharmaceutically acceptable salt thereof, together with
(h) a therapeutically effective amount of an antipsychotic agent,
or a pharmaceutically acceptable salt thereof.

55. (previously presented) A process for preparing *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide comprising reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone with an excess of formic acid and

formamide to provide *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

56. (previously presented) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is of the (*S*) configuration and the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide is a 1:1 mixture of (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

57. (previously presented) The process according to claim 56, further comprising separating the (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide.

58. (previously presented) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is of the (*R*) configuration and the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide is a 1:1 mixture of (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.

59. (previously presented) The process according to claim 58, further comprising separating the (1*R*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide and (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide.

60. (previously presented) The process according to claim 55, wherein the 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone is racemic and the process further comprises separating the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide into *cis* *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl] formamide and *trans* *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide.